Cochrane Review Group
Gynaecology and Fertility
194 systematic reviews in Gynaecology and Fertility ask 2,653 questions. 20% have no studies to answer them, 31.1% rest on very low certainty evidence and 13.8% reach moderate or high certainty.
Reviews
194
Questions
2,653
current versions
No studies
20%
Moderate or high
13.8%
No studies 531 · 20%Ungraded 76 · 2.9%Very low 826 · 31.1%Low 855 · 32.2%Moderate 341 · 12.9%High 24 · 0.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Transvaginal biological graft vs native tissue repair Bladder function · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | RR 12.64 [1.6, 100.06] | 2 studies · 143 participants | Very low |
Transvaginal biological graft vs native tissue repair Quality of life · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | no estimate extracted | 3 studies · 112 participants | Very low |
Transvaginal permanent mesh vs native tissue repair Recurrent prolapse on examination (any compartment) · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | RR 0.42 [0.32, 0.55] | 25 studies · 3680 participants | Very low |
Transvaginal permanent mesh vs native tissue repair Quality of life · vaginal prolapse Transvaginal mesh or grafts or native tissue repair for vaginal prolapse (2024) · Cochrane | no estimate extracted | 9 studies · 1365 participants | Very low |
Summary of findings table ‐ Metformin vs megestrol Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory, or atrophic endometrium · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 4.89 [1.56, 15.32] | 2 studies · 83 participants | Very low |
Summary of findings table ‐ Metformin + megestrol vs megestrol Progression of endometrial hyperplasia to endometrial cancer · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 7.96 [0.16, 402.02] | 3 studies · 156 participants | Very low |
Summary of findings table ‐ Metformin + megestrol vs megestrol Hysterectomy rate · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 7.39 [0.15, 372.38] | 2 studies · 72 participants | Very low |
Summary of findings table ‐ Metformin + megestrol vs megestrol Abnormal uterine bleeding ‐ not measured · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin + megestrol vs megestrol Health‐related quality of life (HRQoL) ‐ not measured · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin + megestrol vs megestrol Adverse effects during treatment · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | 1 study · 8 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory, or atrophic endometrium · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 3.42 [0.13, 88.4] | 1 study · 46 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Recurrence of endometrial hyperplasia ‐ not reported · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Reviews 194
Acupuncture and assisted reproductive technology
CochraneSoF table
2 questions
Acupuncture for menopausal hot flushes
CochraneSoF table
8 questions
Brief co‐incubation of sperm and oocytes for in vitro fertilization techniques
CochraneSoF table
3 questions
Heparin for assisted reproduction
CochraneSoF table
6 questions
FSH replaced by low‐dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques
CochraneSoF table
7 questions
Pre‐operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding
CochraneSoF table
9 questions
Natural cycle in vitro fertilisation (IVF) for subfertile couples
CochraneSoF table
5 questions
Progestagens and anti‐progestagens for pain associated with endometriosis
CochraneSoF table
26 questions
Total versus subtotal hysterectomy for benign gynaecological conditions
CochraneSoF table
3 questions
Selective estrogen receptor modulators (SERMs) for uterine leiomyomas
CochraneSoF table
6 questions
Black cohosh (Cimicifuga spp.) for menopausal symptoms
CochraneSoF table
5 questions
Mifepristone for uterine fibroids
CochraneSoF table
14 questions
Low oxygen concentrations for embryo culture in assisted reproductive technologies
CochraneSoF table
6 questions
Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles
CochraneSoF table
5 questions
Laparoscopic surgery for subfertility associated with endometriosis
CochraneSoF table
4 questions
Soft versus firm catheters for intrauterine insemination
CochraneSoF table
6 questions
Gonadotrophin‐releasing hormone analogues for pain associated with endometriosis
CochraneSoF table
6 questions
Excisional surgery versus ablative surgery for ovarian endometriomata
CochraneSoF table
2 questions
Embryo freezing for preventing ovarian hyperstimulation syndrome
CochraneSoF table
6 questions